This trial is testing immunotherapy treatment with N-803 and pembrolizumab for advanced non-small cell lung cancer. N-803 may activate natural killer cells so that they can stimulate an immune response to help fight cancer. Immunotherapy with monoclonal antibodies, such as pembrolizumab, may help the body's immune system attack the cancer, and may interfere with the ability of tumor cells to grow and spread.
1 Primary · 2 Secondary · Reporting Duration: Up to 2 years
478 Total Participants · 2 Treatment Groups
Primary Treatment: Pembrolizumab · No Placebo Group · Phase 2 & 3
Age Any Age · All Participants · 10 Total Inclusion CriteriaMark “Yes” if the following statements are true for you: